LAG3 and nonpapillary renal cell carcinoma: Recent studies have demonstrated that anti-LAG-3 monotherapy and/or combinations of anti-LAG-3 and anti-PD-1 represent a good treatment for LAG-3+ ccRCC patients who develop an important resistance to anti-PD-1 drugs.